Landos Biopharma (NASDAQ:LABP) Shares Up 6.1%

Shares of Landos Biopharma, Inc. (NASDAQ:LABP) rose 6.1% during mid-day trading on Monday . The stock traded as high as $3.83 and last traded at $3.83. Approximately 3,600 shares changed hands during trading, a decline of 86% from the average daily volume of 25,504 shares. The stock had previously closed at $3.61.

Landos Biopharma Price Performance

The company has a 50 day simple moving average of $3.94 and a 200-day simple moving average of $3.60. The stock has a market cap of $11.95 million, a P/E ratio of -0.79 and a beta of -0.61.

Landos Biopharma (NASDAQ:LABP) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.47. As a group, research analysts expect that Landos Biopharma, Inc. will post -3.26 earnings per share for the current year.

Institutional Investors Weigh In On Landos Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of LABP. Renaissance Technologies LLC lifted its stake in shares of Landos Biopharma by 99.0% in the 1st quarter. Renaissance Technologies LLC now owns 340,500 shares of the company’s stock valued at $502,000 after acquiring an additional 169,400 shares during the last quarter. HRT Financial LP purchased a new position in Landos Biopharma during the 4th quarter valued at about $26,000. BlackRock Inc. increased its holdings in Landos Biopharma by 10.6% during the 1st quarter. BlackRock Inc. now owns 520,308 shares of the company’s stock valued at $767,000 after purchasing an additional 49,880 shares during the period. Vanguard Group Inc. increased its holdings in Landos Biopharma by 30.6% during the 3rd quarter. Vanguard Group Inc. now owns 166,608 shares of the company’s stock valued at $108,000 after purchasing an additional 39,053 shares during the period. Finally, Bank of America Corp DE increased its holdings in Landos Biopharma by 80.4% during the 1st quarter. Bank of America Corp DE now owns 56,321 shares of the company’s stock valued at $83,000 after purchasing an additional 25,096 shares during the period.

About Landos Biopharma

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.